Skip to main content

Find Clinical Trials

Home
Conditions
Lymphoma, Non-Hodgkin

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

229 public trials 24 recruiting studies

Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Completed

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

NCT00117156

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations: Massachusetts General Hospital Boston, Massachusetts, United States

Beth Israel Deaconess Medical Center Boston, Massachusetts, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

University of Rochester Cancer Center Rochester, New York, United States

View Trial Details

Completed

Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma

NCT00644124

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: Sanofi-Aventis Administrative Office Paris, France

View Trial Details

Completed

Ribomustin in the Second Line Therapy of Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma

NCT02072967

Conditions: Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +10 more
Locations: City Clinical Hospital #8 Barnaul, Russia

Chelyabinsk Regional Oncology Dispensary/15 Chelyabinsk, Russia

Vologda Regional Clinical Hospital #2 Cherepovets, Russia

Regional Oncology Dispensary/35 Irkutsk, Russia

View all 35 locations

View Trial Details

Completed

Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab

NCT00240578

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: Not specified

View Trial Details

Completed

A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer

NCT00141297

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: Karmanos Cancer Institute Detroit, Michigan, United States

Memorial Sloan Kettering Cancer Center New York, United States

Abramson Cancer Center Hospital of the University of Pennsylvania Philadelphia, Pennsylvania, United States

Pharmacy/PCAM/West Pavillion Philadelphia, Pennsylvania, United States

View Trial Details

Completed

Cytogenetic Analysis of Bone Marrow Specimen Prior to High Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00534820

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +7 more
Locations: KFSH&RC Riyadh, Saudi Arabia

View Trial Details

Completed

Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT

NCT00534989

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +7 more
Locations: Not specified

View Trial Details

Completed

Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia

NCT00001575

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin's Disease, +8 more
Locations: National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States

View Trial Details

Completed

B-Receptor Signaling in Cardiomyopathy

NCT01135849

Conditions: Adenocarcinoma, Adenoma, Amyloidosis, +140 more
Locations: Stanford University School of Medicine Stanford, California, United States

View Trial Details

Completed

Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab

NCT00240591

Conditions: Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations: Not specified

View Trial Details